Machine Perfusion: Cold versus Warm, versus Neither. Update on Clinical Trials

E. Bonaccorsi-Riani, MD, PhD1,2,* I.M.A. Brüggenwirth, BS3,* J.E. Buchwald, BS4 S. Iesari, MD2,5 P.N. Martins, MD, PhD4

1Abdominal Transplant Unit, Cliniques Universitaires Saint-Luc, Université catholique de Louvain, Brussels, Belgium
2Pôle de Chirurgie Expérimentale et Transplantation, Université Catholique de Louvain, Brussels, Belgium
3Department of Surgery, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
4Division of Transplant, Department of Surgery, UMass Memorial Medical Center, University of Massachusetts, Worcester, Massachusetts
5Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, L’Aquila, Italy

Address for correspondence Paulo N. Martins, MD, PhD, FAST, FEBS, FACS, Division of Transplant, Department of Surgery, UMass Memorial Medical Center, University of Massachusetts, 55 Lake Avenue, Worcester, MA 01655 (e-mail: paulo.martins@umassmemorial.org).


Abstract

Machine perfusion (MP) preservation is potentially one of the most significant improvements in the field of liver transplantation in the last 20 years, and it has been considered a promising strategy for improved preservation and ex situ evaluation of extended criteria donor (ECD) organs. However, MP preservation adds significant cost and logistical considerations to liver transplantation. MP protocols are mainly classified according to the perfusion temperature with hypothermic machine perfusion (HMP) and normothermic machine perfusion (NMP) being the two categories most studied so far. After extensive preclinical work, MP entered the clinical setting, and there are now several studies that demonstrated feasibility and safety. However, because of the limited quality of clinical trials, there is no compelling evidence of superiority in preservation quality, and liver MP is still considered experimental in most countries. MP preservation is moving to a more mature phase, where ongoing and future studies will bring new evidence in order to confirm their superiority in terms of clinical outcomes, organ utilization, and cost-effectiveness. Here, we present an overview of all preclinical MP studies using discarded human livers and liver MP clinical trials, and discuss their results. We describe the different perfusion protocols, pitfalls in MP study design, and provide future perspectives. Recent trials in liver MP have revealed unique challenges beyond those seen in most clinical studies. Randomized trials, correct trial design, and interpretation of data are essential to generate the data necessary to prove if MP will be the new gold standard method of liver preservation.

Keywords

► ex situ machine perfusion
► liver transplantation
► extended criteria donors
► outcomes
► clinical trials
► organ preservation

Over the past five decades, liver transplantation (LT) has become the standard of care for end-stage liver diseases. This success led the liver transplant community to broaden indications for LT.1,2 The direct consequence of this progress is the increasing number of patients on the waiting list, which worsens the chronic problem of organ shortage. In fact, the amount of LTs performed is directly affected by allograft availability, as reflected in the 10 to 20% mortality rate on the waiting list.3,4 To overcome this problem, transplant surgeons are required to accept allografts from

* These authors contributed equally to this work.
donors with extended criteria (ECD), such as elderly donors, obese donors who regularly provide steatotic grafts, and donors after cardiac death (DCD). It is well known that these organs do not tolerate long periods of static cold storage (SCS), the current standard of liver graft preservation, as they are more susceptible to ischemia and reperfusion injury (IRI), have a higher incidence of primary nonfunction (PNF), and are more prone to develop biliary complications, which leads to a greater number of graft failures with a higher rate of retransplantation compared with non-ECD organs. Ex situ organ machine perfusion (MP) can be an alternative preservation modality to improve the quality and function of ECD allografts. The concept of ex situ organ perfusion, idealized by Charles Lindbergh and Alexis Carrel, who built the first MP prototype in 1935, was abandoned after few experiments in the late 1960s performed in the United States and Europe due to improved static cold preservation solutions. The growing demand for ECD organs refueled the interest of the transplant community in MP preservation of ex situ allografts. In the past decade, MP has become a hot topic in organ transplantation and research groups worldwide have investigated different MP modalities to optimize preservation. In this current review, we present an overview of all clinical liver MP trials and MP studies using discarded human liver grafts. We analyzed recent clinical experience with liver MP, taking into account the different protocols with respect to temperature, type of perfusion, duration of perfusion, and post-LT outcome.

**Types of Perfusion**

Ex situ liver perfusion protocols can be mainly defined according to the perfusion temperature used (Fig. 1). In hypothermic machine perfusion (HMP) protocols, the temperature is maintained at 4 to 10°C, while it is around 20 to 30°C in subnormothermic MP studies. In normothermic machine perfusion (NMP), the temperature is kept at physiological levels (37°C). Innovative modalities of organ preservation and perfusion include super cooling organ preservation (−4°C) and hyperthermic perfusion (> 37°C). However, such strategies are still in the experimental stage. While HMP can be performed with or without active oxygenation, NMP always requires oxygenation. Other protocol variations include the perfusion route (through the hepatic artery, portal vein, or both vessels) and the number and kind of pumps (pulsatile vs. nonpulsatile) or via gravitational force like the portal vein perfusion in the OrganOx metra (OrganOx Limited) device.

**Hypothermic Machine Perfusion**

For years, cooling has been the cornerstone in organ preservation. The concept of hypothermic preservation is largely...
based on the idea that the graft is maintained in a hypometabolic state, thereby decreasing energy utilization during ischemia and preserving essential mechanisms to regenerate ATP upon reperfusion. However, due to persistent low-grade cellular metabolism at 4°C, SCS preservation on ice leads to anaerobic metabolism within short time due to the lack of oxygen and substrates. In contrast, the concept of HMP is to maintain viability and aerobic metabolism prior to implantation of the graft by providing oxygen while the organ’s metabolism is limited. The underlying mechanisms in HMP mainly involve resuscitation of mitochondria. Even a short period of 2 hours of oxygenated HMP can switch mitochondria from ischemic to fully recharged cellular energy levels.

MP was traditionally designed as a continuous approach, starting directly after organ procurement. However, in the last decade, it became clear that end-ischemic (after SCS) MP is an attractive and simpler approach, avoiding transportation of the perfusion devices and extra perfusion personnel to the donor hospital. Livers are preserved by SCS after procurement and are then subjected to end-ischemic MP upon arrival at the recipient center. Even after relatively longer periods of SCS, end-ischemic HMP can protect liver grafts. An additional advantage of HMP is that in case of pump failure, the liver can easily be restored to traditional SCS. Also, since the organ is in a hypometabolic state, it produces less waste products and requires less intensive labor by perfusionists when compared with NMP. A disadvantage of HMP used to be the lack of reliable prediction methods of organ function. However, a recent study by Muller et al shows that real-time fluorometric analysis of perfusate flavin, a marker of mitochondrial injury, can be predictive of graft function and loss during cold MP. This achievement has high clinical relevance, and real-time estimation of liver function during cold preservation could substantially increase safe utilization of liver grafts.

**Prospective Clinical Studies Using Hypothermic Machine Perfusion**

In 2010, Guarrera et al were the first to report successful transplantation of 20 ECD donation after brain death (DBD) human livers after HMP via the portal vein and hepatic artery without active oxygenation (Table 1). Because this was a nonrandomized trial comparing a series of machine-perfused livers with historical controls, they were only able to demonstrate safety of end-ischemic HMP of human liver grafts during 3 to 7 hours. This was also the first study to describe that the HMP system is user-friendly, such as that MP pressures and temperature remained stable, and little intervention from the perfusionist was needed. They found diminished peak aspartate aminotransferase (AST) and alanine aminotransferase (ALT), shorter hospital length of stay, and fewer biliary complications in the HMP-treated grafts compared with the matched SCS group. In the years following, HMP was increasingly used in kidney transplantation worldwide, but clinical implantation in LT remained investigational. Five years after publishing their first clinical series, Guarrera et al reported successful transplantation of 31 “orphan” ECD livers after preservation by HMP in a nonrandomized fashion. The term orphan was denoted to any liver turned down by all centers within the donor’s originating United Network for Organ Sharing region, requiring more complex allocation management and expected longer cold ischemia time (CIT). Their study shows good outcomes with 84% graft survival 1 year after transplantation. In addition, biliary complications, often described as the “Achilles heel” of LT, occurred significantly less in the HMP group compared with the SCS historical control group. Better preservation of the arteriolar vasculature lining the biliary tree by providing a continuous supply of oxygen, better distribution of the perfusion fluid, and washout of waste products is suggested to play a role. In the same year, Dutkowski et al reported on a nonrandomized study of 25 DCD livers treated by oxygenated HMP (HOPE) through the portal vein only. Lower peak ALT, lesser cases of intrahepatic cholangiopathy and biliary complications, and 1-year graft survival of 90% versus 69% were observed in the HOPE group compared with the SCS historical control group. Although conclusive evidence of a beneficial effect of HMP on reducing biliary injury after transplantation could not yet be provided, these first results seemed promising. In 2017, van Rijn and colleagues published a nonrandomized clinical study of end-ischemic dual HOPE (DHOPE) in 10 DCD liver grafts. Compared with SCS alone, DHOPE seemed to provide better preservation of DCD liver grafts, resulting in reduced graft injury and improved early graft function. Noteworthy, none of the 10 DHOPE-preserved livers required retransplantation for nonanastomotic biliary strictures (NAS), compared with 5 out of 20 in the control group. The potential benefit of DHOPE to better preserve the biliary tree is investigated in a randomized clinical trial (RCT), initiated by Groningen et al in 2015 (clinicaltrials.gov; NCT02584283) and of which the results are expected mid-2020. In collaboration between liver transplant centers in the Netherlands, the United Kingdom, and Belgium, this trial investigates the impact of DHOPE preservation versus SCS in DCD liver grafts. The primary outcome of the DHOPE-DCD trial is the development of NAS within 6 months after LT. Single HOPE is investigated by the prospective HOPE-EC-DBD clinical trial started in 2017 by the University of Aachen. In this RCT using DBD livers only, 1 to 2 hours of single HOPE preservation is compared with the traditional SCS (clinicaltrials.gov; NCT03124641).

The results of two single-center trials from France and Italy may be expected this year. The PIO trial from Italy compares 10 ECD livers treated with HOPE with 30 matched historical controls preserved by SCS (clinicaltrials.gov; NCT03031067). The PERHO trial from France compares 25 DCD livers preserved by HOPE with 75 historical controls preserved by SCS (NCT03376074). The results of several other clinical trials may be expected in the coming years. As such, a large RCT in the United States is investigating HMP versus SCS in 140 transplant recipients with the incidence of early allograft dysfunction (EAD) as its primary outcome (NCT03484455). The multicenter HOPExt trial from France randomizes 266 ECD liver grafts between HOPE and SCS, also studying EAD as its primary outcome (NCT03929523). Similarly, an RCT in France
<table>
<thead>
<tr>
<th>Author or organization</th>
<th>Year</th>
<th>Donor type (DCD/DBD)</th>
<th>N total (HMP/SCS)</th>
<th>Perfusion characteristics</th>
<th>Perfsate</th>
<th>Total time of preservation (min)</th>
<th>Endpoints</th>
<th>Outcome (HMP vs. SCS)</th>
</tr>
</thead>
<tbody>
<tr>
<td>PI: Stefania Camagni, Bergamo, Italy&lt;sup&gt;a&lt;/sup&gt;</td>
<td>Estimated completion date: 2022</td>
<td>Not reported</td>
<td>20 (20/0)</td>
<td>Device not reported. HA &lt; 30 mm Hg/PV &lt; 5 mm Hg. Time on machine: 4h</td>
<td>UW-MPS</td>
<td>Results awaited</td>
<td>Primary: incidence of PRS. Secondary: entity of IRI, incidence of EAD</td>
<td>Results awaited</td>
</tr>
<tr>
<td>PI: Mickael Lesurtel, Lyon, France&lt;sup&gt;b&lt;/sup&gt;</td>
<td>Estimated completion date: 2022</td>
<td>DBD</td>
<td>266 (133/133)</td>
<td>Device: Liver Assist. PV only. Time on machine: 1–4 h</td>
<td>UW-MPS</td>
<td>Results awaited</td>
<td>Primary: incidence of EAD. Secondary: MEAF score, L-GrAFT, metabolic profiling, PRS, 90-d morbidity/mortality, length of hospital stay, MCRP within 1 y, 3-mo/1-y graft/patient survival, hospital costs</td>
<td>Results awaited</td>
</tr>
<tr>
<td>PI: Matteo Ravaioli, Bologna, Italy&lt;sup&gt;c&lt;/sup&gt;</td>
<td>Estimated completion date: 2021</td>
<td>DBD</td>
<td>110</td>
<td>Device not reported. Oxygenated (500–600 mm Hg)</td>
<td>UW-MPS</td>
<td>Results awaited</td>
<td>Primary: incidence of EAD. Secondary: surgical complications, liver function at 6/12 mo, patient survival at 6/12 mo</td>
<td>Results awaited</td>
</tr>
<tr>
<td>Organ Recovery Systems&lt;sup&gt;d&lt;/sup&gt;</td>
<td>Estimated completion date: 2021</td>
<td>Not reported</td>
<td>140</td>
<td>Device: LifePort Liver Transporter</td>
<td>Vassosol</td>
<td>Results awaited</td>
<td>Primary: incidence of EAD</td>
<td>Results awaited</td>
</tr>
<tr>
<td>PI: Robert Porte, Groningen, The Netherlands&lt;sup&gt;e&lt;/sup&gt;</td>
<td>Completion date: 2019</td>
<td>DCD</td>
<td>156 (78/78)</td>
<td>Device: Liver Assist. HA 25–30 mm Hg / PV &lt;5 mm Hg. Oxygenated (50–70 kPa) Time on machine: 1 h</td>
<td>UW-MPS</td>
<td>Results awaited</td>
<td>Primary: incidence of NAS at 6 mo. Secondary: graft/patient survival, PNF, IPT, recipient hemodynamics during LT, hospital length of stay, postoperative complications, liver function and injury markers, costs of treatment, quality of life</td>
<td>Results awaited</td>
</tr>
<tr>
<td>PI: Georg Lurje (Aachen, Germany)&lt;sup&gt;f&lt;/sup&gt;</td>
<td>Completion date: 2019</td>
<td>DBD</td>
<td>46 (23/23)</td>
<td>Device: Liver Assist. HA &lt;3 mm Hg. Oxygenated (150–200 mm Hg) Time on machine: 2h</td>
<td>IGL-1</td>
<td>Results awaited</td>
<td>Primary: postoperative peak ALT in the first postoperative week. Secondary: Dindo/Clavien classification, hospital and ICU stay, IRI, 1-y patient/graft survival</td>
<td>Results awaited</td>
</tr>
<tr>
<td>Renes University Hospital&lt;sup&gt;h&lt;/sup&gt;</td>
<td>Completion date: 2019</td>
<td>DBD</td>
<td>25 (25/0)</td>
<td>Device not reported. PV &lt;3 mm Hg. Oxygenated (40 kPa) Time on machine: 2h</td>
<td>UW-MPS</td>
<td>Results awaited</td>
<td>Primary: incidence of PNF/EAD. Secondary: nr of intraoperative transfusions, PRS, morbidity on day 7, graft survival at 3 mo, hospital length of stay, cost of initial stay, cost of the hospitalization stay</td>
<td>Results awaited</td>
</tr>
<tr>
<td>PI: Matteo Ravaioli, Bologna, Italy&lt;sup&gt;i&lt;/sup&gt;</td>
<td>Completion date: 2018</td>
<td>DBD</td>
<td>10 (10/0)</td>
<td>Device: Exper, Bologna Machine Perfusion. Oxygenated (80–100 kPa) Time on machine: 2h</td>
<td>Not reported</td>
<td>Results awaited</td>
<td>Primary: graft function at 3 mo. Secondary: graft/patient survival at 3 mo</td>
<td>Results awaited</td>
</tr>
</tbody>
</table>

(Continued)
<table>
<thead>
<tr>
<th>Author or organization</th>
<th>Year</th>
<th>Donor type (DCD/DBD)</th>
<th>N total (HMP/SCS)</th>
<th>Perfusion characteristics</th>
<th>Perfusate</th>
<th>Total time of preservation (min) (range)</th>
<th>Endpoints</th>
<th>Outcome (HMP vs. SCS)</th>
</tr>
</thead>
<tbody>
<tr>
<td>van Rijn et al[28]</td>
<td>2017</td>
<td>HMP 10/0 SCS 20/0</td>
<td>30 (10/20)</td>
<td>Device: Liver Assist HA 20–30 mm Hg/PV 5 mm Hg; 500 mL/min 100% O₂; Time on machine: 126 min (123–135)</td>
<td>UW-MPS</td>
<td>HMP: 521 (469–592); SCS: 503 (476–526)</td>
<td>Primary: graft survival at 6 mo. Secondary: 1-y graft/patient survival, technical safety, perfusate microbiology, postoperative complications</td>
<td>100 vs. 80%; 6-mo graft survival, 100 vs. 67%; 1-y graft survival, 100 vs. 85%; 1-y patient survival. No technical problems. Peak ALT (IU/L): 966 vs. 1,858. NAS: 0/10 vs. 5/20</td>
</tr>
<tr>
<td>Dutkowski et al[27]</td>
<td>2015</td>
<td>HMP 25/0 SCS 50/0</td>
<td>75 (25/50)</td>
<td>Device: ECOPS device PV 120–180 mL/min Oxygenated Time on machine: 118 min (101–149)</td>
<td>KPS-1</td>
<td>HMP: 317 (280–391); SCS: 395 (349–447)</td>
<td>Primary: incidence and severity of biliary complications within 1 y after LT. Secondary: liver IRI and function, graft survival</td>
<td>Ischemic cholangiopathy: 0% vs. 22%. Biliary complications: 20% vs. 46%. Peak ALT (IU/L): 1,239 vs. 2,065.</td>
</tr>
<tr>
<td>Guarrera et al[25]</td>
<td>2015</td>
<td>HMP 0/31 SCS 0/30</td>
<td>61 (31/30)</td>
<td>Device: Medtronic PBS 0.667 mL/g/liver/min No active oxygenation Time on machine: 258 ± 54 min</td>
<td>Vassol</td>
<td>HMP: 564 ± 96; SCS: 534 ± 144</td>
<td>Primary: incidence of PNF, EAD, and vascular complications, 1-y graft/patient survival. Secondary: incidence of biliary complications, AKI, hospital length of stay, liver/kidney function markers</td>
<td>PNF: 3% vs. 7%. EAD: 19% vs. 30%. Vascular complications: 9% vs. 7%. 84% vs. 80% 1-y patient survival. Biliary complications: 4/31 vs. 13/30 AKI: 10% vs. 27%. Hospital stay: 13.6 d vs. 20.1 d</td>
</tr>
<tr>
<td>Guarrera et al[23]</td>
<td>2010</td>
<td>HMP 0/20 SCS 0/20</td>
<td>40 (20/20)</td>
<td>Device: Medtronic PBS 0.667 mL/g/liver/min No active oxygenation Time on machine: 228 ± 54 min</td>
<td>Vassol</td>
<td>HMP: 558 ± 126; SCS: 516 ± 168</td>
<td>Primary: incidence of PNF, EAD, and vascular complications, 1-y graft/patient survival. Secondary: incidence of biliary and vascular complications, AKI, hospital length of stay, liver/kidney function markers</td>
<td>No PNF in either group. EAD: 5% vs. 25%. No vascular complications in either group. 90% vs. 90% 1-y graft/patient survival. Biliary complications: 2/20 vs. 5/20. Hospital stay: 10.9 d vs. 15.3 d. Peak ALT (IU/L): 560 vs. 1,358</td>
</tr>
</tbody>
</table>

Abbreviations: AKI, acute kidney injury; ALT, alanine aminotransferase; D, duration; DBD, donation after brain death; DCD, donation after circulatory death; DHOPE, dual hypothermic oxygenated machine perfusion solution; EAD, early allograft dysfunction; ECD, extended criteria donor; h, hours; HA, hepatic artery; HMP, hypothermic machine perfusion; IGL-1, Institute George Lopez solution; HOPE, hypothermic oxygenated machine perfusion; KPS-1, kidney perfusion solution; IRI, ischemia-reperfusion injury; L-GrAFT, liver graft assessment following transplantation risk factor; LT, liver transplantation; MEAF, model of early allograft function; MP, machine perfusion; NAS, nonanastomotic biliary strictures; PNF, primary nonfunction; PRS, postreperfusion syndrome; PV, portal vein; SCS, static cold storage; UW-MPS, University of Wisconsin machine perfusion solution.

Trial name: HOPE with Cytokine Filtration in Liver Transplantation (Cyto-HOPE); NCT04203004.
Trial name: HOPE for Extended Criteria Donors in Liver Transplantation (HOPEext); NCT03929523.
Trial name: Clinical Trial of New HOPE System Versus SCS; NCT03837197.
Trial name: Post-SCS HOPE in Bergamo Liver Transplant Program; NCT03098043.
Trial name: Study to Evaluate Performance of LifePort Liver Transporter System, a Machine Perfusion System, for Liver Transplant (PILOT); NCT03484455.
Trial name: DHOPE of DCD Liver Grafts in Preventing Biliary Complications after Transplantation (DHOPE-DCD); NCT02584283.
Trial name: HOPE for Human ECD and DBD Liver Allografts (HOPE-ECD-DBD); NCT03124641.
Trial name: Interest of Oxygenated Hypothermic Perfusion in Preservation of Hepatic Grafts from ECD (PERPHO); NCT03376074.
Trial name: HOPE versus SCS for Margina Graft (PIO); NCT03031067.
Hypothermic Machine Perfusion in Experimental Studies Using Discarded Human Livers

The majority of studies published on HMP over the last decades involve mainly preclinical studies without implantation of the graft. Instead, reperfusion with whole blood and reoxygenation is used to simulate transplantation. Most experimental studies have used animal models to investigate different HMP modalities, and to date, only a handful of studies using discarded human livers have been published (Table 3).

There is a wide variance in the reported HMP perfusion times. In general, HMP perfusion protocols are shorter than for NMP. Perfusion durations up to 7 hours have been reported in clinical studies, but a period of 1 to 2 hours of end-ischemic HMP is most commonly used. Cold oxygenation restores cellular energy levels already within the first 1 to 2 hours of perfusion. In addition, a short period of 2 hours of HMP seems to improve endothelial cell function as evidenced by increased nitric oxide production and endothelial cell stability. However, the effect did not persist during reperfusion, making it unlikely to have an effect in a real transplant setting.

Caution should be given to the perfusion devices’ pressure settings during HMP, as higher vascular resistances in the cold pose a risk of undesired endothelial shear stress to the liver sinusoids. Some of the currently used perfusion devices are flow-controlled, such as the Medtronic PBS used by Guarrera et al, whereas others are pressure-controlled, like the Liver Assist from Organ Assist used by Porte et al. Based on recent studies, adjusting MP settings to portal pressures of ≤ 3 mm Hg and arterial pressures of ≤ 25 mm Hg can avoid shear stress.

Regarding the perfusion route, two different approaches have been advocated. Single portal vein perfusion adds simplicity and has been shown to mitigate IRI of the liver parenchyma and biliary tree. Complete perfusion of the liver and the biliary system during single portal vein perfusion was shown by fluorescence in rat, pig, and discarded human livers. However, researchers opting for a dual perfusion route suggest improved oxygen supply to the peribiliary vascular plexus of the bile ducts by additional arterial perfusion. In a feasibility study using discarded human livers, Jomaa et al found no effect of using a dual versus single MP approach on sinusoidal endothelial injury. On another note, arterial perfusion only does not seem to be a favorable approach. In clinical trials, Dutkowski et al have repeatedly used single HOPE, whereas Guarrera et al and van Rijn et al used dual HOPE in their series.

Mitigating biliary IRI and reducing ischemic cholangiopathy remain a lofty goal for DCD LT in particular. It remains unknown whether dual perfusion is superior to prevent ischemic cholangiopathy after transplantation, and only randomized trials comparing a single versus dual approach could answer this question. Currently, the only clinical trial compares HOPE versus SCS in 110 ECD livers with EAD as the primary outcome (NCT03837197). A smaller single-center study from the Papa Giovanni XXIII Hospital in Italy aims to study the feasibility and safety of HOPE in their liver transplant program in 20 patients (NCT03098043). In 2020, the same hospital plans to start a RCT to study the effects of HOPE using a cytokine filter (cyto-HOPE) versus traditional HOPE in 20 ECD livers (NCT04203004). The primary outcome of the trial is the incidence of post-reperfusion syndrome in the recipient, hypothesizing that cytokine filtration further reduces IRI during HOPE.
studying the effects of DHOPE uses DCD livers, whereas single HOPE is used in a prospective trial in DBD grafts. A recent report by van Leeuwen et al describes feasibility of HMP through the umbilical vein instead of the portal vein in discarded human livers.53 Portal venous flows were similar to those observed after cannulation of the portal vein main stem. MP through the umbilical vein could enable continuous oxygenated perfusion of liver grafts during procurement, splitting, and implantation.

A variety of MP solutions have been explored during HMP, with Belzer MP solution, histidine–tryptophan–kelifglutamate preservation solution, Polysol, Celsior, Institut Georges Lopez preservation solution, and UW gluconate being the most routinely used.29 The majority of clinical perfusions are based on the original or modified UW solution. Solutions with low potassium concentrations and without the presence of starch appear particularly advantageous. A low potassium concentration decreases vascular resistance under hypothermic conditions and the addition of starch has been shown to increase perfusate viscosity.44 Under HMP, there is no need to add an oxygen carrier and the transport of oxygen is done passively though dilution.

Normothermic Machine Perfusion

In this MP preservation protocol, as the name implies, the temperature of the perfusate is maintained at “normal,” physiological levels at 37°C. The objective of mimicking the physiological environment is to keep the metabolic activity of the organ as close as possible to normal levels to minimize the impact of IRI, thereby increasing viability of the organ. To do this, NMP requires the use of oxygenators and the presence of oxygen transporters in the perfusate, with human red blood cells being the most common oxygen transporter used in current protocols.45–50 Unlike the HMP configuration, in NMP protocols, liver grafts are normally perfused through the portal vein and the hepatic artery. The maintenance of the organ metabolic activity during NMP offers the possibility to assess organ viability by measuring many metabolic parameters, such as lactate clearance, pH and glycemic levels, as well as bile production and its composition.51 Finally, normothermic conditions seem to offer a more adequate setting for organ modulation, such as the use of defatting cocktails or gene therapies during ex situ perfusion.

Prospective Clinical Studies Using Normothermic Machine Perfusion

While two case reports were initially published online before 2016 describing LTs performed with ECD livers after preservation by NMP, the first multicenter clinical trial comparing NMP versus SCS was conducted by the Oxford group being published by Ravikumar et al in 2016 (Table 2).45,52,53 In this nonrandomized study, which was designed to assess the viability and safety of NMP by comparing 20 LTs after NMP preservation with 40 LTs using SCS preservation (20% of DCD grafts in each group), no differences were observed in 30-day graft and patient survival rates and in 6-month patient survival rates between the two groups.53 Later, two other non-RCTs conducted independently at two Canadian transplant centers, using the same Oxford perfusion device, confirmed the feasibility and safety of NMP.46,47 Selzner et al of the Toronto group compared 10 NMP-preserved livers with a matched historical series of 30 transplanted livers using SCS. The proportion of DCD livers was 20% in the NMP group and 27% in the control group, and both groups presented similar graft and patient survival rates at 1 month, without differences in graft function in the early stages.46 The second clinical trial conducted at the University of Alberta, with a similar study design, confirmed the absence of differences in graft survival rates at 1 and 6 months after transplantation. It is worth noting that one DCD liver was discarded shortly after connection to the machine due to a hidden portal venous twist that prevented organ perfusion.47 In July 2014, the Oxford team initiated the first European multicenter RCT on NMP to extensively assess graft function and survival at 6 months and 1 year, as well as patient morbidity and mortality. This study, published in 2018, compared 121 patients who received an NMP-preserved liver with 101 patients transplanted with SCS-preserved livers. They showed lower rates of EAD and reperfusion syndrome. However, no differences were observed in the overall complication rates, hospital and intensive care unit length of stay, and 1-year graft and patient survival rates. Noteworthily, the NMP group had 28% of DCD grafts versus 21% in the SCS group, and with longer functional warm ischemia time and total preservation time compared with the SCS group. Furthermore, there was no significant difference in the rate of biliary complications (anastomotic and nonanastomotic strictures) between the two groups, neither for DCD nor DBD grafts at the MRCP performed at 6 months post-LT.48 Recently, the Pisa group conducted the first RCT to investigate the impact of NMP on LT with older donors. Twenty grafts from donors aged ≥70 years were randomized in a 1:1 ratio to NMP or SCS preservation. There was no statistical difference in the patient and graft survival rates at 6 months. A patient in the NMP group received a second graft due to hepatic artery thrombosis 10 days after LT. On the other hand, one patient in the SCS group died 31 days after LT due to an episode of intestinal occlusion that evolved into sepsis shock.49 A single-center study from the Cleveland group tested the use of fresh-frozen plasma (FFP) as a constituent of the perfusate in association with RBC units. Using a noncommercial custom-made perfusion device, Liu et al compared the outcome of 21 LT performed with NMP-preserved livers to a historical series of LT performed with livers preserved by SCS in a 1:4 ratio. The NMP group presented less EAD, no cases of biliary complications, and the only death in this group was due to a cerebral vascular accident 8 months after LT.50 Recently, Jassem et al reanalyzed liver tissue samples and hepatic mononuclear cells collected from DBD livers transplanted after NMP and initially published by Ravikumar et al. They observed that NMP changed the gene expression profile from proinflammation to prohealing and regeneration compared with SCS liver samples. In addition, they observed a reduction in the population of T cells that produce inflammatory factors and an increase in the pool of regulatory T cells in NMP livers. These livers presented less necrosis and apoptosis and less neutrophil...
<table>
<thead>
<tr>
<th>Author or organization</th>
<th>Year</th>
<th>Donor type (DCD/DBD)</th>
<th>N total (NMP/SCS)</th>
<th>Perfusion characteristics</th>
<th>Perfuse</th>
<th>Total time of preservation (min) (range)</th>
<th>Endpoints</th>
<th>Outcome (NMP vs. SCS)</th>
</tr>
</thead>
<tbody>
<tr>
<td>PI: Cristiano Quintini, The Cleveland Clinic</td>
<td>Ongoing Completion date: 2023</td>
<td>Results awaited</td>
<td>15</td>
<td>Device: Institutional Liver MP Device</td>
<td>Not reported</td>
<td>Results awaited</td>
<td>Primary: 30-d posttransplantation rate of survival and PNF, Secondary: EAD, 6-mo graft survival, liver function, and injury markers</td>
<td>Results awaited</td>
</tr>
<tr>
<td>PI: Cristiano Quintini, The Cleveland Clinic</td>
<td>Ongoing Completion date: 2022</td>
<td>ECD</td>
<td>15</td>
<td>Device: Institutional Liver MP device</td>
<td>Not reported</td>
<td>Results awaited</td>
<td>Primary: patient/graft survival at 1 mo Secondary: EAD, patient/graft survival at 6 mo, blood loss, liver function, and injury markers, hospital/ICU length of stay</td>
<td>Results awaited</td>
</tr>
<tr>
<td>PI: James Shapiro, University of Alberta</td>
<td>Ongoing Completion date: 2021</td>
<td>Results awaited</td>
<td>50</td>
<td>Device: OrganOx metra</td>
<td>Not reported</td>
<td>Results awaited</td>
<td>Primary: 30-d graft survival Secondary: 30-d patient survival, EAD</td>
<td>Results awaited</td>
</tr>
<tr>
<td>PI: Cristiano Quintini, The Cleveland Clinic</td>
<td>Ongoing Completion date: 2020</td>
<td>Results awaited</td>
<td>25</td>
<td>Device: Institutional Liver MP device</td>
<td>Not reported</td>
<td>Results awaited</td>
<td>Primary: incidence of EAD Secondary: PNF, 6 mo graft/patient survival, 7-d peak liver function tests, intra-op flow measurement, PRS, intra-op surgical outcomes, kidney failure, biliary/vascular complications at 6 mo, hospital/ICU stay, rejection rate at 6 mo, opportunistic viral infection rate</td>
<td>Results awaited</td>
</tr>
<tr>
<td>PI: Stuart Knechtle, Duke University</td>
<td>Ongoing Completion date: 2020</td>
<td>Results awaited</td>
<td>266</td>
<td>Device: OrganOx metra</td>
<td>Not reported</td>
<td>Results awaited</td>
<td>Primary: incidence of EAD Secondary: PNF, graft/patient survival, PRS, liver function and injury markers, biliary complications, incidence of livers randomized but not transplanted, organ utilization, healthcare costs, quality-of-life measures</td>
<td>Results awaited</td>
</tr>
<tr>
<td>PI: Darius Mirra, University Hospital Birmingham</td>
<td>Ongoing Completion date: 2020</td>
<td>Results awaited</td>
<td>22</td>
<td>Device: OrganOx metra</td>
<td>Not reported</td>
<td>Results awaited</td>
<td>Primary: 90-d patient survival, use of NMP to identify the proportion of transplantable liver grafts from currently rejected donor organ pool Secondary: 12-mo liver graft function, 90-d morbidity associated with receipt</td>
<td>Results awaited</td>
</tr>
<tr>
<td>Author or organization</td>
<td>Year</td>
<td>Donor type DC/DBD</td>
<td>N total (NMP/SCS)</td>
<td>Perfusion characteristics</td>
<td>Perfsusate</td>
<td>Total time of preservation (min) (range)</td>
<td>Endpoints</td>
<td>Outcome (NMP vs. SCS)</td>
</tr>
<tr>
<td>------------------------</td>
<td>------</td>
<td>-------------------</td>
<td>-------------------</td>
<td>---------------------------</td>
<td>------------</td>
<td>-----------------------------------------</td>
<td>-----------</td>
<td>----------------------</td>
</tr>
<tr>
<td>TransMedics'</td>
<td>Ongoing</td>
<td>Completion date: 2020</td>
<td>Results awaited</td>
<td>300</td>
<td>Device: TransMedics OCS</td>
<td>Not reported</td>
<td>Results awaited</td>
<td>Primary: Incidence of EAD, SAEs in first 30 d</td>
</tr>
<tr>
<td>de Vries et al69</td>
<td>2019</td>
<td>DHOPE-COR-NMP 7/0</td>
<td>7 (7/0)</td>
<td>Device: Liver Assist Pressure DHOPE: HA: 11 mm Hg PV: 5 mm Hg Pressure NMP: HA: 70 mm Hg PV: 11 mm Hg Flow NMP: HA: 0.55 L/min (0.24–0.73) PV: 1.7 L/min (01.46–1.74)</td>
<td>HBOC-201</td>
<td>Total MP time: 427 (283–517)</td>
<td>Primary: graft survival at 3 mo</td>
<td>100% 3 mo graft survival</td>
</tr>
<tr>
<td>Ghinolfi et al69</td>
<td>2019</td>
<td>NMP 0/10 SCS 0/10</td>
<td>20 (10/10)</td>
<td>Device: Liver Assist Flow: HA: 0.205–0.420 L/min PV: 1.1–1.7 L/min Time on machine: 4.2 h (3.25–4.7)</td>
<td>Gelofusine (B Braun) + AB- O-compatibleRBC concentrate</td>
<td>NMP: 246 (206–267) SCS: 394 (366–465)</td>
<td>Primary: graft/patient survival at 6 mo Secondary: peak transaminases within 7 d, biliary complications at 6 mo</td>
<td>No PNF in either group. EAD: 2/10 vs. 1/10. Peak ALT (IU/L): 332 (263–610) vs. 428 (303–1,162). Graft survival: 90 vs. 100%. Patient survival: 100 vs. 90%. Biliary complication: 1/10 vs. 0/10</td>
</tr>
<tr>
<td>Liu et al50</td>
<td>2019</td>
<td>NMP 8/13 SCS 17/68</td>
<td>105 (21/84)</td>
<td>Device: Noncommercial, institutional apparatus Flow: HA: 0.5 L/min (0.2–0.7) PV: 1.6 L/min (1.1–2.1) Time on machine: 3.35–7.89 h</td>
<td>4 units of blood bank-obtained FFP + 4 units of PRBC</td>
<td>NMP: 528 (462–594) SCS: 498 (408–588)</td>
<td>Primary: safety, feasibility, and impact on intrahepatic hemodynamics of FFP Secondary: prove safety and feasibility of a noncommercial, institutional perfusion apparatus</td>
<td>No PNF in either group. EAD: 19 vs. 46.4%, p = 0.02. Peak ALT (IU/L): 363 ± 318 vs. 1,021 ± 999. No cases of ischemic cholangiopathy. Patient survival: NMP: 95.2% (One patient died of intracranial hemorrhage on postoperative month 8 with normal liver function). Mortality in the historical control group not reported</td>
</tr>
<tr>
<td>Nasralla et al48</td>
<td>2018</td>
<td>NMP 34/87 SCS 21/80</td>
<td>221 (121/101)</td>
<td>Device: OrganOx metro Flow: HA: 0.28 L/min PV: 1.1 L/min Time on machine: 9.13 h (1.42–24)</td>
<td>Gelofusine (B Braun) + 3-unit donor-matched PRBC</td>
<td>NMP: 714 (258–1527) SCS: 465 (223–967)</td>
<td>Primary: peak level of serum AST within 7 d after LT Secondary: organ discard rate, PRS, PNF, EAD, length of hospital/ICU stay, RRT, cholangiopathy on MRCP at 6 mo, graft/patient survival at 1 y</td>
<td>PNF: 0.8 vs. 0%. EAD: 10 vs. 30%. Peak AST (IU/L): 488 (408.9–582.8) vs. 964 (794.5–1,172.0). Patient survival at year: 95.8 vs. 97%. Graft survival at year: 95 vs. 96%</td>
</tr>
<tr>
<td>Watson et al45</td>
<td>2018</td>
<td>NMP 35/12</td>
<td>47 (47/0)</td>
<td>Device: Liver Assist Pressure: HA: 60 mm Hg PV: 8–10 mm Hg Flow: not reported Time on machine: 4 h</td>
<td>Leukocyte depleted red cells + Gelofusine (B Braun) or Steen solution</td>
<td>NMP: 460–1,388</td>
<td>Primary: observation of biochemistry and perfusion characteristics</td>
<td>22 livers were transplanted. 1 recipient died following PNF, 1 developed EAD, 4 developed ITBL (3 required re-LT)</td>
</tr>
<tr>
<td>Author or organization</td>
<td>Year</td>
<td>Donor type</td>
<td>N/total (NMP/SCS)</td>
<td>Perfusion characteristics</td>
<td>Per fusate</td>
<td>Total time of preservation (min) (range)</td>
<td>Endpoints</td>
<td>Outcome (NMP vs. SCS)</td>
</tr>
<tr>
<td>------------------------</td>
<td>------</td>
<td>------------</td>
<td>-------------------</td>
<td>--------------------------</td>
<td>-----------</td>
<td>-----------------------------------------</td>
<td>-----------</td>
<td>----------------------</td>
</tr>
<tr>
<td>Watson et al&lt;sup&gt;65&lt;/sup&gt;</td>
<td>2017</td>
<td>NMP 9/3</td>
<td>12 (12/0)</td>
<td>Device: Liver Assist Pressure: HA: 60 mm Hg PV: 8–10 mm Hg Flow: not reported Time on machine: 284 (122–350)</td>
<td>Leukocyte depleted red cells + Gelofusine (B Braun) or Steen solution</td>
<td>NMP: 778 (564–1,561)</td>
<td>Primary: assessment of viability in declined marginal livers and research livers</td>
<td>5/6 developed PRS, 4 sustained vaso-plegia, 1 PNF, 3 DCD livers developed cholangiopathy</td>
</tr>
<tr>
<td>Bral et al&lt;sup&gt;67&lt;/sup&gt;</td>
<td>2017</td>
<td>NMP 4/6 SCS 8/22</td>
<td>39 (10/30)</td>
<td>Device: OrganOx metra Pressure: Not reported. Flow: not reported. Time on machine: 3 h</td>
<td>Gelofusine (B Braun) + 3-unit type &quot;O&quot; PRBC</td>
<td>NMP: 786 (304–1,631) SCS: 235 (64–890)</td>
<td>Primary: 30-d graft survival Secondary: patient survival at day 30, peakAST within 7 d, EAD, liver function and injury markers, Clavien-Dindo score, graft/patient survival at 6 mo, biliary complications at 6 mo</td>
<td>No PNF in either group. EAD: 55.5 vs. 29.6%. Peak AST (IU/L): 1,252 (383–2,600) vs. 839 (153–2,600). 6 mo graft survival: 80 vs. 100% 6 mo patient survival: 89 vs. 100% 6 mo biliary complications 0% (0/8) vs. 14.8% (4/27), p = 0.55</td>
</tr>
<tr>
<td>Mergental et al&lt;sup&gt;63&lt;/sup&gt;</td>
<td>2016</td>
<td>NMP 4/2</td>
<td>6 (6/0)</td>
<td>Device: Liver Assist, OrganOx Pressure: not reported. Flow: HA: 0.53 L/min (0.36–0.62) PV: 1.1 L/min (0.7–1.5) Time on machine: 3 h</td>
<td>Blood-based</td>
<td>NMP: 798 (724–951)</td>
<td>Primary: demonstrate feasibility of rejected allografts transplanted following assessment and resuscitation by NMP</td>
<td>Uneventful transplant procedure in all 5 transplanted patients and immediate function recovery in all grafts. Normalized liver tests at median follow-up of 7 mo. One graft did not fulfill viability criteria after 3 h of MP</td>
</tr>
<tr>
<td>Selzner et al&lt;sup&gt;65&lt;/sup&gt;</td>
<td>2016</td>
<td>NMP 2/8 SCS 8/24</td>
<td>40 (10/30)</td>
<td>Device: OrganOx metra Pressure: not reported. Flow: HA: 0.3 L/min (0.2–0.4) PV: 1.25 L/min (1.2–1.3) Time on machine: 8 h (5.7–9.7)</td>
<td>3 units of PRBC + Steen solution</td>
<td>NMP: 586 (221–731) SCS: 634 (523–783)</td>
<td>Primary: assess safety and feasibility of NMP</td>
<td>Peak ALT (IU/L): 619 (55–2,858) vs. 949 (233–3,073). 3 mo graft/patient survival 100% in both groups</td>
</tr>
<tr>
<td>Ravikumar et al&lt;sup&gt;65&lt;/sup&gt;</td>
<td>2016</td>
<td>NMP 4/16 SCS 8/32</td>
<td>60 (20/40)</td>
<td>Device: OrganOx metra Pressure: HA 60–75 mm Hg PV not reported. Flow: HA = 0.2 L/min PV = 0.8 L/min Time on machine: 9.3 h (3.5–18.5)</td>
<td>3 units of cross-matched PRBC + 1 unit of Gelofusine (B Braun)</td>
<td>Not reported</td>
<td>Primary: 30-d graft survival Secondary: liver function and injury markers within 7 d after LT, patient/ graft survival at 6 mo</td>
<td>No PNF in either group. EAD: 15 vs. 22.5%. Peak AST (IU/L): 417 (84–4,861) vs. 902 (218–8,761)/ 30-d graft survival: 100 vs. 97.5%. 6 mo patient survival: 100 vs. 97.5%</td>
</tr>
</tbody>
</table>

Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; D, duration; DBD, donor after brain death; DCD, donor after circulatory death; EAD, early allograft dysfunction; ECD, extended criteria donors; FFP, fresh frozen plasma; GGT, gamma-glutamyl transferase; h, hours; HA, hepatic artery; HAT, hepatic artery thrombosis; ICU, intensive care unit; INR, international normalized ratio; IRI, ischemia–reperfusion injury; LT, liver transplantation; MAP, mean arterial pressure; MP, machine perfusion; MRCP, magnetic resonance imaging scan of biliary tree; MRS, magnetic resonance spectroscopy; POD, postoperative day; NCT, national clinical trial identifier; NMP, normothermic machine perfusion; PI, principal investigator; PNF, primary nonfunction; PRBC, packed red blood cells; PRS, postreperfusion syndrome; PV, portal vein; RRT, renal replacement therapy; SAEs, serious adverse events; SCS, static cold storage.

aTrial name: Safety and Feasibility of NMP to Preserve and Evaluate Orphan Livers; NCT03456284.
bTrial name: Efficacy of Ex-situ NMP versus Cold Storage in the Transplant with Steatotic Liver Graft (ORGANOXLAFE); NCT03930459.
cTrial name: Sequential Hypo- and Normothermic Perfusion to Preserve Extended Criteria Donor Livers for Transplantation; NCT04023773.
dTrial name: Using Ex-Vivo NMP With the OrganOx Metra Device to Store Human Livers for Transplantation; NCT02478151.
eTrial name: Normothermic Liver Preservation Trial; NCT03089840.
fTrial name: Pilot Study to Assess Safety and Feasibility of NMP in Human Liver Transplantation; NCT02515708.
gTrial name: WP01—Normothermic Liver Preservation; NCT02775162.
hTrial name: Viability Testing and Transplantation of Marginal Livers (VITTAL); NCT02740608.
iTrial name: TransMedics (OCS) Liver PROTECT; NCT02522871.
<table>
<thead>
<tr>
<th>Author</th>
<th>Year</th>
<th>Donor type</th>
<th>MP (n)</th>
<th>Perfusion characteristics</th>
<th>Perfusate</th>
<th>D (h)</th>
<th>Aim/Endpoints</th>
<th>Main outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abudhaise et al35</td>
<td>2018</td>
<td>DCD/DBD</td>
<td>38</td>
<td>4–8°C HA 30 mm Hg/PV 7 mm Hg 0.5 L/min 100% O₂</td>
<td>KPS-1</td>
<td>4</td>
<td>Dynamic, biochemical, and histological markers during HMP</td>
<td>Single arterial perfusion had higher resistance, lower flows, and higher perfusate markers compared with single portal venous perfusion. No differences between oxygen-supplemented vs. non-oxygen-supplemented perfusion</td>
</tr>
<tr>
<td>Burlage et al41</td>
<td>2017</td>
<td>DCD/DBD</td>
<td>6</td>
<td>10°C HA 25 ± 5 mm Hg/PV 5 mm Hg 1 L/min 100% O₂</td>
<td>UW-MPS</td>
<td>2</td>
<td>Endothelial cell function</td>
<td>NO levels increased during reperfusion in HMP livers, but not in controls. Cumulative TM release was lower in HMP livers</td>
</tr>
<tr>
<td>Westerkamp et al30</td>
<td>2016</td>
<td>DCD/DBD</td>
<td>6</td>
<td>10°C HA 25 ± 5 mm Hg/PV 5 mm Hg 1 L/min 100% O₂</td>
<td>UW-MPS</td>
<td>2</td>
<td>Hepatobiliary function and injury</td>
<td>ATP levels, bile production, biliary bilirubin, and biliary HCO₃⁻ were higher, and lactate and glucose levels were lower in HMP livers. No differences in hepatobiliary injury markers</td>
</tr>
<tr>
<td>Schlegel et al40</td>
<td>2016</td>
<td>DCD</td>
<td>3</td>
<td>10°C PV 2.5–3 mm Hg Oxygenated (40–60 kPa)</td>
<td>KPS-1</td>
<td>n/a</td>
<td>Complete perfusion of liver grafts</td>
<td>Fluorescence under dark light confirmed complete perfusion of liver grafts by single arterial perfusion</td>
</tr>
<tr>
<td>van Leeuwen et al43</td>
<td>2019</td>
<td>DCD</td>
<td>3</td>
<td>10–12°C UV 5 mm Hg Oxygenated</td>
<td>UW-MPS</td>
<td>n/a</td>
<td>Assess feasibility of machine perfusion via the umbilical vein</td>
<td>HMP through the umbilical vein is feasible. Portal venous flows were similar to those obtained after cannulation of the portal main stem</td>
</tr>
<tr>
<td>Jomaa et al42</td>
<td>2013</td>
<td>DBD/DCD</td>
<td>12</td>
<td>4–8°C HA 30 mm Hg/PV 7 mm Hg</td>
<td>KPS-1</td>
<td>1</td>
<td>Feasibility study</td>
<td>Pressures and temperature were maintained throughout the perfusions. No differences in sinusoidal endothelial ultrastructure between the groups. Sterility was maintained. Single or dual perfusion did not affect vascular resistance or flow</td>
</tr>
<tr>
<td>Monbaliu et al36</td>
<td>2012</td>
<td>DBD/DCD</td>
<td>17</td>
<td>4–6°C HA 20–30 mm Hg/PV 7 mm Hg No active oxygenation</td>
<td>UW-MPS</td>
<td>24</td>
<td>Explore whether quality of livers could be assessed during HMP</td>
<td>Nontransplantable livers released more AST and LDH than transplantable livers. Vascular resistances and metabolic profiles did not differ between transplantable vs. nontransplantable livers</td>
</tr>
<tr>
<td>Vekemans et al29</td>
<td>2011</td>
<td>DBD/DCD</td>
<td>13</td>
<td>5–8°C HA 20 mm Hg/PV 3 mm</td>
<td>KPS-1</td>
<td>4</td>
<td>Test the clinical validity of end-ischemic HMP</td>
<td>Lower AST and LDH in HMP livers. Morphological scores were similar. MAPK was downregulated by HMP</td>
</tr>
<tr>
<td>Author</td>
<td>Year</td>
<td>Donor type</td>
<td>MP (n)</td>
<td>Perfusion characteristics</td>
<td>Perfusate</td>
<td>D (h)</td>
<td>Aim/Endpoints</td>
<td>Main outcomes</td>
</tr>
<tr>
<td>-----------------</td>
<td>------</td>
<td>------------</td>
<td>--------</td>
<td>---------------------------</td>
<td>-------------------------------------</td>
<td>-------</td>
<td>---------------------------------------------</td>
<td>---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Guarrera et al</td>
<td>2005</td>
<td>Not reported</td>
<td>10</td>
<td>Hg 3–5 mm Hg/PV 12–18 mm Hg No active oxygenation</td>
<td>Vasosol</td>
<td>5–10</td>
<td>Develop a reproducible technique for liver HMP</td>
<td>The described method for HMP appeared to be safe and reliable to preserve livers</td>
</tr>
<tr>
<td>Liu et al</td>
<td>2018</td>
<td>DCD/DBD 12</td>
<td>37°C</td>
<td>HA 60–100 mm Hg PV 5–10 mm Hg Oxygenated</td>
<td>Matched RBC + FFP from blood bank</td>
<td>24</td>
<td>Determine effect of NMP on steatosis and markers of hepatic quality during NMP</td>
<td>Active lipid metabolism present in all livers as measured by perfusate triglyceride, total cholesterol, and lipoprotein concentrations. Lactate levels undergo 3 phases during NMP: priming-to-peak phase, clearance phase, and steady-state phase</td>
</tr>
<tr>
<td>Mergental et al</td>
<td>2018</td>
<td>DCD/DBD 5</td>
<td>37°C</td>
<td>HA 50 mm Hg PV 10 mm Hg Non-lactate-clearing (n = 6) Lactate-clearing (n = 6) Oxygenated</td>
<td>3 units of donor-specific blood group + Rhesus-negative + PRBC</td>
<td>6</td>
<td>Develop a standardized protocol for NMP with a functional assessment of rejected donor livers and to propose liver viability criteria</td>
<td>Viability criteria composed of lactate clearance, pH maintenance, bile production, vascular flow patterns, and liver macroscopic appearance</td>
</tr>
<tr>
<td>Boteon et al</td>
<td>2018</td>
<td>DCD/DBD 13</td>
<td>37°C</td>
<td>HA 256–760 mL/min HA 30–50 mm Hg PV 926–1,500 mL/min PV 8–10 mm Hg Oxygenated</td>
<td>4 units of hemoglobin-based oxygen carrier</td>
<td>6</td>
<td>Comparative study of 2 perfusion strategies to restore ECD livers</td>
<td>NMP + HOPE livers achieved lower expression of markers of oxidative injury and inflammation compared with NMP alone. All 5 livers in NMP + HOPE group achieved viability criteria, but 40% in NMP-only group failed</td>
</tr>
<tr>
<td>Vogel et al</td>
<td>2017</td>
<td>DCD/DBD 5</td>
<td>37°C</td>
<td>HA 17.2–18.6 mm Hg IVC 2.22–1.66 mm Hg Oxygenated</td>
<td>3–4 units of compatible PRBC + Sterofundin</td>
<td>24</td>
<td>Analysis of discarded liver grafts that underwent NMP for extended 24 h</td>
<td>NMP preservation for 24 h demonstrated to be technically feasible even in suboptimal donor organs. Positive correlation between perfusion parameters and accepted predictors of posttransplant graft survival</td>
</tr>
<tr>
<td>Karimian et al</td>
<td>2015</td>
<td>DCD/DBD 12</td>
<td>37°C</td>
<td>MAP 70 mm Hg HA 240–272 mL/min PV 714–782 mL/min PV 11 mm Hg 4 L/min at 100% O₂</td>
<td>PRBC + FFP + albumin</td>
<td>6</td>
<td>Demonstrate feasible protocol for ex situ NMP using dual-perfusion device</td>
<td>Initial increase in HA and PV flow. Increase in concentration of total bilirubin and bicarbonate in bile. ATP content increased during NMP. Stable concentrations of hepatic injury markers demonstrated minimal graft injury during</td>
</tr>
</tbody>
</table>
Normothermic Machine Perfusion in Experimental Studies Using Discarded Human Livers

Studies Using Discarded Human Livers

Similar to what happened in the HMP scenario, experimental animal studies, mainly using porcine models, anticipated preclinical, experimental studies of NMP with discarded human livers. Sutton et al demonstrated the viability of NMP in a group of four discarded DCD livers showing a decrease in lactate levels and bile production during a 6-hour NMP protocol. In addition, Sutton et al. used a 6-hour NMP protocol after discard of DCD livers during a decrease in lactate levels. The objective of identifying biomarkers and parameters of organ viability, as well as to investigate the time limit of NMP (Table 3). In this way, op den Dries et al demonstrated feasibility of NMP in discarded livers and identified two patterns of bile flow identified: steadily increasing bile production and cumulative bile production. Livers in low bile output group demonstrated signs of hepatic necrosis and venous congestion vs. high bile output group.

Table 3 (Continued)

<table>
<thead>
<tr>
<th>Author</th>
<th>Year</th>
<th>Donor type</th>
<th>MP (n)</th>
<th>Perfusion characteristics</th>
<th>Perfusate</th>
<th>D (h)</th>
<th>Aim/Endpoints</th>
<th>Main outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sutton et al</td>
<td>2014</td>
<td>DCD/DBD</td>
<td>12</td>
<td>37°C, HA 60 mm Hg, PV 11 mm Hg</td>
<td>Heparinized plasma + PRBC</td>
<td>6</td>
<td>Assess whether bile production is a suitable biomarker of graft viability</td>
<td>NMP. Histological examination revealed no additional injury to grafts</td>
</tr>
<tr>
<td>op den Dries et al</td>
<td>2013</td>
<td>DCD</td>
<td>4</td>
<td>37°C, HA 50 mm Hg, PV 11 mm Hg</td>
<td>PRBC + FFP, blood group and Rhesus factor identical to donor liver</td>
<td>6</td>
<td>Demonstrate feasibility of NMP in discarded livers</td>
<td>Biochemical markers in perfusion fluid demonstrated minimal hepatic injury and improving function. Lactate levels decreased to normal values. Bile production throughout perfusion period. Histological examination demonstrated preserved morphology, without signs of ischemia or injury</td>
</tr>
</tbody>
</table>

This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.
6.5 hours of SCS, to show that livers with low bile production have more signs of necrosis and hepatic congestion compared with livers with high bile output. However, more recent studies underline the importance of bile composition instead of mere bile production. Karimian et al established a detailed technical protocol for NMP with dual perfusion in 12 ECD livers and Vogel et al showed that within 24 hours of NMP, there is a positive correlation between perfusion parameters and accepted predictors of post-LT graft survival. The Cleveland group evaluated the effect of 24 hours of NMP on lipid metabolism in steatotic livers. They showed active lipid metabolism over time with an increase in triglyceride levels and a decrease in total cholesterol, high-density lipoprotein, and low-density lipoprotein cholesterol, suggesting that MP can be used for lipid modulation. After a preclinical study that evaluated the viability criteria in 12 ECD livers, Mergental et al reported a series of five transplanted livers with an eventful postoperative period in all cases. The Cambridge group published about their NMP experiences in two articles where they initially assessed the impact of different O2 tensions in the perfusate during NMP of 12 discarded ECD livers. A high O2 tension was associated with an increased risk of post-reperfusion syndrome and sustained vasoplegia. In total, 47 livers were perfused using NMP, and 20 livers were transplanted from a group of 28 livers accepted for possible transplantation. In addition, 2 livers were transplanted from a group of 19 livers initially declined for transplantation. One recipient died due to PNF and one presented EAD, and three out of four recipients who developed perihepatic biliary lesions required a retransplantation. Although MP offers the possibility of increasing the group of transplantable livers due to all the advantages mentioned earlier, these results remind us that care must be taken not to push the limits too far when deciding to implant an initially declined liver. Van Leeuwen et al recently proposed a decision-making algorithm based on both hepatocellular (liver parenchyma) and cholangiocyte (bile duct) function (see section “Hypothermic followed by Normothermic Machine Perfusion”). In addition, we hope that the results of the Viability Testing and Transplantation of marginal Livers (VITTAL study), an ongoing prospective clinical trial, can provide more information on the algorithm to decide which initially discarded liver should be transplanted (NCT02740608; Table 2).

**Hypothermic followed by Normothermic Machine Perfusion**

In a proof-of-concept preclinical work, Boteon et al tested a sequential protocol of 2 hours of HOPE and subsequent 6 hours of NMP, which was compared with NMP alone. The combination of HOPE and NMP leads to a lower expression of oxidative stress markers, with all livers achieving viability criteria against only 40% of livers in the NMP group. This strategy, which aims to combine the advantages of HMP to resuscitate the energy levels of the organ and reduce cell injury with the functional evaluation of the organ provided by the NMP, was subsequently explored in the clinical setting by the Groningen group. De Vries et al enrolled 20 discarded livers in a single-arm prospective clinical trial of initial DHOPE followed by an intermediate phase of controlled oxygenated rewarming before the final NMP period (DHOPE-COR-NMP). Seven of the 20 livers were subjected to the DHOPE-COR-NMP protocol, 5 met the LT viability criteria during 2.5 hours of NMP, while 2 livers were declined for transplantation during the NMP evaluation. All transplanted livers reached the primary endpoint of 3-month graft survival. These results motivated the Groningen group to conduct a national prospective clinical trial where initially declined livers underwent the same DHOPE-COR-NMP protocol using an acellular perfusion solution containing a hemoglobin-based oxygen carrier, HBOC-201 (Hemopure; HbO2 Therapeutics LLC). Sixteen livers were enrolled and 69% (11/16) of them met all the viability criteria, including lactate < 1.7 mmol/L, perfusate pH 7.35 to 7.45, bile production > 10 mL, and bile pH > 7.45 within the first 2.5 hours of NMP. All 11 livers were successfully implanted and the patient and graft survival rates were 100% at 3 and 6 months.

**Logistical Aspects of Machine Perfusion**

Based on the studies reviewed here, we believe that MP is a promising technology for organ rescue and function assessment and improvement. However, its implementation in clinical practice will require caution from the transplant community. Due to logistical and operational reasons, end-stage MP will probably be used in the clinical situation, instead of immediate MP at the donor hospital as happened in some initial clinical trials. Because of its high costs, MP is expected to be reserved for organs at high risk of developing complications of PNF and EAD post-LT, such as ECD organs (e.g., DCD, steatosis, advanced age, expected prolonged CIT, and hemodynamically unstable donors). In addition, MP is time-consuming and requires experienced personnel to set up the machine, place the organ, and monitor the perfusion session. It will probably increase the already overloaded work time of many transplant teams. In general, we believe that the accepting surgical team should be responsible for placement of the organ on the device and its initial monitoring. Special trained organ perfusionists may be responsible for monitoring the organ during MP. Centers might need to establish either a specialized perfusion room or use one of the operating rooms, as cannulation and perfusion of the organ must be performed in a location that meets the current standards for performing sterile procedures. Currently, the cost of MP devices available on the market is around US$ 100,000 (Fig. 2). Disposable sets cost from US$ 5,000 to 30,000 per unit. In general, the additional cost of MP per transplant is estimated between US$ 25,000 and 50,000 considering the device, disposable, personnel, blood products, increased donor operation room time, etc. It raises the question of who will be responsible for these extra costs: the transplant center that pumps the organ, or in case that the organ is perfused by the allocation agency (e.g., OPO in the United States and Eurotransplant in Europe) should the extra costs be shared by all centers under its jurisdiction?
This additional cost be covered by all medical insurances? These questions and many others raised by the future implementation of MP in clinical practice were highlighted by a committee of experts on organ perfusion and published by Quintini et al in 2018 on behalf of the American Society of Transplant Surgeons. As indicated, the answers to all questions will require the participation of the entire liver transplant community, including transplant centers, allocation agencies, medical insurance organizations, and scientific associations.

**Pitfalls in Machine Preservation Studies**

As with any clinical trial, it is extremely important to avoid selection biases. This is particularly important for organ transplantation, as both characteristics of recipient and the graft can have a tremendous impact on outcomes. It is very important to randomize the groups and the randomization process needs to be done after the organ has been accepted and not at the time of the donor offer. Although attempts are made, there are currently no widely accepted criteria for transplantability of a liver graft. Unconscious biases may influence the decision to accept or decline an organ at the time of the procurement. To transplant grafts that were initially declined by all centers in the region but later successfully transplanted after MP does not necessarily mean that those organs were nonviable prior to MP—pointing to several studies showing good outcomes for “livers-that-nobody-wants.”

Another limitation for clinical trials of MP is that it requires large sample sizes (and increased costs) for variables that are infrequent like PNF and ischemic cholangiopathy. Therefore, it seems more reasonable to perform clinical trials using ECD organs, like DCD and severely steatotic organs, until more data are available.

It is also very important to choose the right endpoints when designing clinical trials. The primary endpoint needs to be of significant clinical relevance. A surrogate endpoint has been defined as “a biomarker that is intended to substitute for a clinical endpoint” and generally is considered valid given a more rapid and frequent incidence and strong association with traditional endpoints. Obtaining statistical significance for irrelevant endpoints does not mean superiority for MP. For example, peak transaminase posttransplant has been used in several studies and even as the primary endpoint in a RCT. We believe peak transaminases posttransplant should not be used as primary endpoint in machine preservation trials for two reasons. First, transaminases have not been shown to have an important clinical significance in both the liver donor and post-LT settings, unless extremely high. Second, since the grafts in the MP trials are flushed with several extra liters of preservation solution, part of the transaminases accumulated in the liver before transplantation are eliminated, and they have a long half-life (17 hours for AST, 47 hours for ALT). Therefore, if transaminases are going to be used as secondary endpoints, ideally the grafts from the control arm (standard cold preservation) should be flushed with the same amount of fluid used in the perfusion circuit just before implantation to minimize the differences related to the wash-out phenomenon.

**Conclusion**

Over the last decade, MP of donor livers has gained considerable interest as an approach to resuscitate and assess ECD
livers prior to transplantation. After extensive preclinical work, prospective clinical trials increased the evidence of the beneficial effects of MP over SCS preservation. It is still early to definitively confirm that MP is superior to SCS preservation in regard to graft and patient survival. We need to wait for more RCTs comparing MP with SCS preservation, as well as comparing different modalities of machine preservation. Likely, all modalities of MP could have a role in the clinical setting with each having pros and cons in different situations. There are grounds for optimism that MP leads to better preservation of the biliary tree with less expected ischemic cholangiopathy. Besides, there has been a lot of progress toward optimizing MP in terms of duration, perfusion solution, and temperatures used. Within the area of liver MP, we are now progressing toward a more individualized approach based on donor organ characteristics. In the coming years, it should become clear which organ would benefit most from MP and under which preservation conditions (e.g., hypothermic, normothermic, or both). The sequential strategy of HMP followed by NMP seems to combine the advantages of both protocols, the restoration of cellular energy with the possibility to evaluate organ function, and providing conditions for organ modulation and reconditioning. As such, genetic modulation therapies can be administered during MP to improve post-OLT outcome. In the future, the development of nanoparticles may be translated into clinical use with the potential to mitigate organ damage through a variety of mechanisms. More studies are needed to address these strategies. On the other hand, important logistical issues related to costs, MP reimbursement, personnel in charge, time, and place of the MP session must be addressed to move MP from the research environment to a reality in the clinical practice of LT. Altogether, we can expect that, in the coming years, the field of liver preservation will become even more interesting with new technologies and more evidence through clinical trials.

Main Concepts and Learning Points

- Machine perfusion is a feasible and safe procedure for organ preservation.
- Hypothermic oxygenated machine perfusion effectively restores cellular energetic capital within few hours of perfusion.
- Normothermic machine perfusion may be more adequate to assess organ viability during the perfusion session.
- Further clinical trials are required to define in which clinical scenario MP will be superior to SCS and cost-effective.

Authors’ Contributions
E.B.-R., I.M.A.B., J.B., S.I., and P.N.M. contributed to conception and design, acquisition of data, and analysis and interpretation of data. E.B.-R., I.M.A.B., and P.N.M. drafted the article and revised it critically for important intellectual content. P.N.M. approved the final version to be published.

Conflicts of Interest
None.

References


McCormack I, Quiñoñez E, Ríos MM, et al. Rescue policy for discarded liver grafts: a single-centre experience of...